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Preparation and evaluation of azithromycin binary solid dispersions 
using various polyethylene glycols for the improvement of the drug 
solubility and dissolution rate
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The International Branch, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Azithromycin is a water-insoluble drug, with a very low bioavailability. In order to increase the solubility 
and dissolution rate, and consequently increase the bioavailability of poorly-soluble drugs (such as 
azithromycin), various techniques can be applied. One of such techniques is “solid dispersion”. This 
technique is frequently used to improve the dissolution rate of poorly water-soluble compounds. Owing 
to its low solubility and dissolution rate, azithromycin does not have a suitable bioavailability. Therefore, 
the main purpose of this investigation was to increase the solubility and dissolution rate of azithromycin 
by preparing its solid dispersion, using different Polyethylene glycols (PEG). Preparations of solid 
dispersions and physical mixtures of azithromycin were made using PEG 4000, 6000, 8000, 12000 and 
20000 in various ratios, based on the solvent evaporation method. From the studied drug release profile, 
it was discovered that the dissolution rate of the physical mixture, as the well as the solid dispersions, 
were higher than those of the drug alone. There was no chemical incompatibility between the drug and 
polymer from the observed Infrared (IR) spectra. Drug-polymer interactions were also investigated using 
Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD) and Scanning Election 
Microscopy (SEM). In conclusion, the dissolution rate and solubility of azithromycin were found to 
improve significantly, using hydrophilic carriers, especially PEG 6000.
Uniterms: Azithromycin/solubility. Azithromycin/dissolution. Solid dispersion. Polyethylene glycols.
A azitromicina é um fármaco insolúvel em água, com biodisponibilidade muito baixa. A fim de 
aumentar a taxa de solubilidade e dissolução e, consequentemente, aumentar a biodisponibilidade de 
fármacos fracamente solúveis (tais como azitromicina), várias técnicas podem ser aplicadas. Uma dessas 
técnicas é a “dispersão sólida”, frequentemente usada para melhorar a taxa de dissolução de compostos 
fracamente solúveis em água. Devido à baixa taxa de solubilidade e de dissolução, este fármaco não 
tem biodisponibilidade adequada. Portanto, o principal objetivo desta pesquisa foi o de aumentar a taxa 
de solubilidade e dissolução da azitromicina, preparando a sua dispersão sólida, utilizando diferentes 
glicóis de polietileno (PEG). As dispersões sólidas e as misturas físicas de azitromicina foram preparadas 
utilizando PEG 4000, 6000, 8000, 12000 e 20000, em várias proporções, com base no método de 
evaporação do solvente. O perfil de liberação do fármaco foi estudado e verificou-se que tanto a taxa de 
dissolução da mistura física quanto as dispersões sólidas foram maiores do que as do fármaco sozinho. 
Espectros de IR não revelaram incompatibilidade química entre o fármaco e o polímero. Interações 
fármaco-polímero também foram investigadas usando calorimetria diferencial de varredura (DSC), 
Difração de Raios X (PXRD) e Microscopia Eletrônica de Varredura(SEM). Em conclusão, a taxa de 
dissolução e a solubilidade da azitromicina melhoraram, de forma significativa, utilizando suportes 
hidrofílicos, especialmente PEG 6000.
Unitermos: Azitromicina/solubilidade. Azitromicina/dissolução. Dispersão sólida. Polietilenoglicóis.
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INTRODUCTION
Azithromycin (Figure 1) is a semi-synthetic antibiotic 
obtained from erythromycin. It is a Macrolide antibiotic. 
This drug is a nitrogen-containing macrolide (Azalide), 
with indications and usage similar to Erythromycin. All 
macrolides, such as azithromycin inhibit RNA dependent 
protein synthesis by binding reversibly to the 50S 
ribosomal subunits of susceptible microorganisms (Patil 
et al., 2011; Montejo-Bernardo et al., 2005; Beckers et al., 
1995; Champney, Burdine, 1998). This antibiotic is one 
of the world’s best-selling antibiotics, and is currently the 
world’s most widely consumed antibiotic (WIPO, 2012). 
The dihydrate form of this drug is a white crystalline 
powder, with a molecular formula of C38H72N2O12.2H2O 
and molecular weight of 748.984 g.mol-1 (Moffat et al., 
2011; USP, 2007; Amidon, 1995). It is used orally for the 
treatment of bronchitis, certain types of skin infections, 
sore throat, pharyngitis, tonsillitis, nosocomial infections 
and pneumonia. The excellent activity against Chlamydia 
trachomatis is its unique feature (Sweetman, 2009). It is 
prescribed for the treatment of respiratory-tract infections 
(including otitis media) and also for skin and soft-tissue 
infections. Azithromycin can also be used for prophylaxis, 
and act as a component of drug regimen in the treatment of 
Mycobacterium avium complex (MAC) infections. It has 
activity against gram-positive organisms and also offers 
an increased gram-negative coverage over erythromycin 
and clarithromycin (Moffat et al., 2011; Sweetman, 2009; 
Palanisamy, Khanam, 2011).
Poorly water-soluble drugs could create problems 
regarding decreased drug effectiveness. Majority of the 
drugs, which are soluble in small amounts of water, have 
low bioavailability. The effort to improve the dissolution 
and solubility of a poorly water-soluble drug remains one 
of the most challenging tasks in drug development. Many 
approaches are used to increase the dissolution rate of 
drugs, including solid dispersion, chemical modification, 
micronization, co‐solvency, complexation, pH adjustment, 
and micellar-solubilization.
The use of solid dispersions in improving the 
solubility of poorly water-soluble drugs dates back to 1961 
(Sekiguchi, Obi, 1961; Patil et al., 2013; Damian et al., 
2000). Solid dispersions could be prepared by different 
methods, including melting, solvent and melting-solvent 
techniques (Patil et al., 2013; Chiou, Riegelman, 1971). 
One common method in preparing solid dispersions is 
the melt-congealing or solvent evaporation method (Al-
Hamidi et al., 2010; Han et al., 2011). The transformation 
of drugs in solid dispersions from amorphous form to 
crystalline form is a critical obstacle in making solid 
dispersions and a practical approach in the pharmaceutical 
industry. However, the utilization of surface adsorbents 
can be a useful approach to tackle this problem (Li et al., 
2011; Patil, Gaikwad, 2011; Leuner, Dressman, 2000; 
Adeli, Mortazavi, 2014). It involves the formation of 
eutectic mixtures of drug with water-soluble carriers, 
by melting their physical mixtures. After dissolving the 
carrier, the drug precipitates in a finely divided state in 
water. Different mechanisms are considered for drug 
solubility and dissolution rate enhancement, using solid 
dispersions. Particle size reduction of drug to submicron 
size and the consequent increase in surface area seem to be 
the most important (Okonogi, Puttipipatkhachorn, 2006; 
Mura et al., 2005; Craig, 2002). 
The solid dispersion technique has been used for 
a wide variety of poorly water-soluble drugs such as 
irbesartan (Adeli, 2015), nimesulide (Babu et al., 2003) 
and ursodeoxycholic acid (Okonogi et al., 1997). One 
major problem associated with azithromycin is its very 
poor solubility (belongs to BCS class II) in biological 
fluids which accounts for the poor bioavailability, upon 
its oral administration. In this study, the solid dispersion 
method was utilized in order to increase the dissolution rate 
and solubility of azithromycin. Although there have been 
previous studies on this technology for over half-a-century, 
its application in drug development has attained greater 
importance since early 1990s owing to the widespread 
application of combinatorial chemistry and high-throughput 
screening in drug discovery, which favors the selection 
of poorly water-soluble new chemical entities (NCEs) 
(Vasanthavada et al., 2008; Pudipeddi et al., 2006).
MATERIAL AND METHODS 
Material
Azithromycin dihydrate, PEG 4000, PEG 6000, 
FIGURE 1 - Chemical structure of azithromycin (Adeli, 2014).
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PEG 8000, PEG 12000 and PEG 20000 were purchased 
from Fluka, USA. Sodium hydrogen phosphate, sodium 
hydroxide and ethanol 96% were purchased from Merck, 
USA. All the chemical reagents used were of analytical 
grade.
Methods
Preparation of physical mixtures
With great precision, 100 mg of pure azithromycin 
and appropriate amounts of PEG (4000, 6000, 8000, 12000 
and 20000) in various drug-to-carrier weight ratios were 
weighed and thoroughly blended in a glass mortar for 
5 min (as an example, PM1 (1:1) was prepared by 100 mg 
of azithromycin and 100 mg of PEG 4000, PM9 (1:7) 
was prepared by 100 mg of azithromycin and 700 mg of 
PEG 6000, similarly to PM25 (1:9), which was prepared 
by 100 mg of azithromycin and 900 mg of PEG 20000). 
The composition of various batches is shown in Table 
I. The physical mixtures were prepared by weighing 
the calculated amounts of azithromycin, followed by 
trituration mixture of the carrier (PEG) with the drug in a 
glass mortar. The samples prepared were kept for further 
studies.
Preparation of solid dispersions
Solid dispersions of azithromycin were prepared 
in drug: carrier weight ratios as 1:1, 1:3, 1:5, 1:7 and 
1:9, using the solvent evaporation method. 100 mg of 
azithromycin dihydrate was dissolved in 10 mL of 96% 
ethanol and the carrier was then added and dissolved 
at 40 °C, following continuous mixing on a hot plate 
to obtain a clear solution. Afterwards, the solvent was 
allowed to evaporate. The prepared solid dispersions 
(Table I) were collected, sieved, and stored in desiccators 
until subsequent analysis. The process of evaporation was 
opted until a constant weight was obtained. Overall, the 
yield was approximately 98%.
Analysis of azithromycin dihydrate
Azithromycin was analyzed at 215 nm (USP, 2007; 
IP, 2007) using a UV spectrophotometer. The standard 
curve for the determination of drug was constructed by 
dissolving it in phosphate buffer pH = 6.0, in concentration 
range of 2 to 30 μg/mL. In this concentration range, good 
linearity was observed (R2 = 0.9998). The graph obeyed the 
Beer-Lambert’s law in the selected concentration range.
Determination of drug content
Drug content was determined by dissolving 
accurately weighed quantities of binary systems of drug, 
carrier, and adsorbent in pH = 6.0 buffer. The solutions 
were filtered and diluted appropriately followed by a 
spectrophotometrical measurement of samples at 215 nm 
using SHIMADZU-UVmini 1240 Spectrophotometer, 
Japan (USP, 2007; IP, 2007).
Saturation solubility studies
To evaluate the increase in drug solubility, solid 
dispersions and the physical mixtures, saturation solubility 
test was carried out. Excess amounts (approximately 
100 mg) of the drug was added to 100 mL of phosphate 
buffer (pH = 6.0). Samples were stirred at 200 RPM at 
25 °C for 24 h, filtered, suitably diluted and analysed by a 
UV spectrophotometer at 215 nm.
Dissolution studies
In vitro release studies of azithromycin, solid 
dispersions, and the physical mixtures were carried out in 
a USP Apparatus 2 (Erweka DT6R, Germany) at 100 rpm 
in 900 mL of phosphate buffer (pH = 6.0) maintained at 
37.0 ± 0.5 °C (USP, 2007). Dissolution studies were carried 
out using 100 mg of the pure drug and an equivalent amount 
of individual sample preparations. Aliquots of 5 mL were 
withdrawn at specified time intervals of 5, 10, 15, 20, 30, 
45 and 60 min and replaced with equal volumes of fresh 
medium. The resultant samples were filtered through 
Whatman filter paper and analyzed spectrophotometrically 
at 215 nm, for the determination of dissolved drug. The 
dissolution studies were carried out in triplicate (Deepti, 
Madan, 2007).
Dissolution Efficiency (DE)
Dissolution efficiency (DE) is a parameter for 
evaluation of in vitro dissolution data. It is the area under 
the dissolution curve divided by the rectangular area that 
shows 100% of the solute at a certain time. This parameter 
is equal to the total area under the curve of the dissolution 
curve, at time “t” (between two time-points, expressed 
as a percentage of the curve at maximum dissolution). 
DE can also be expressed as percentage of the area of the 
rectangle described by 100% dissolution at the same time. 
Dissolution efficiency (DE%) was calculated to compare 
the dissolution data (Anderson et al., 1998). Where:”y” is 
the percent drug dissolved at the time “t”.
Infrared (IR) spectroscopy
The IR spectra of azithromycin, solid dispersion 
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and the physical mixture were obtained using an IR 
spectrometer (PerkinElmer 843 System, USA). About 2 to 
3 mg of the test sample was mixed with dry KBr and the 
spectra were obtained over a wavenumber range of 4000 
to 200 cm-1. An average of 20 scans was taken.
Differential scanning calorimetry (DSC)
Differential scanning calorimetry thermograms 
of pure the pure drug, PEG 6000, solid dispersions 
and all the other preparations were obtained using a 
SHIMADZU DSC-60instrument (Japan). The calorimeter 
was calibrated using Indium as standard at 156.6±1 °C. 
Accurately weighed samples (6.00 mg) were crimped 
in aluminum pans and heated from 20.0 to 200.0 °C at 
a heating rate of 10 °C/min in nitrogen atmosphere. An 
empty sealed aluminum pan was used as the reference.
Powder X-Ray Diffraction (PXRD)
Powder X-ray diffraction patterns of plain 
azithromycin, pure PEG 6000, solid dispersions of 
Azithromycin and the physical mixtures were recorded 
using a powder X-ray diffract meter (PHILIPS PW 1800 
X-Ray Diffraction Machine, The Netherlands) with 
a copper tube anode over the interval 5-90° 2θ-1. The 
TABLE I - Drug content and saturation solubility studies of pure Azithromycin, solid dispersions and physical mixtures (n = 3, 
mean ± SD)
Carrier 
Formulation 
code
Preparation 
Drug: Carrier 
(w/w)
Theoretical drug content Assayed drug content Saturation 
solubility 
(μg/mL)
Amount (mg) Expressed (%) Amount (mg) Expressed (%)
- Azithromycin Pure drug 1:0 100 100 99.92 ± 1.27 99.92 85 ± 1.08
PEG 4000
SD1 Solid dispersion 1:1 50 100 49.82 ± 0.33 99.64 185 ± 1.24
SD2 Solid dispersion 1:3 25 100 24.77 ± 0.22 99.08 227 ± 2.04
SD3 Solid dispersion 1:5 16.67 100 16.44 ± 0.13 98.62 235 ± 1.91
SD4 Solid dispersion 1:7 12.5 100 12.26 ± 0.07 98.08 241 ± 1.45
SD5 Solid dispersion 1:9 10 100 9.76 ± 0.07 97.57 243 ± 1.88
PM4
Physical 
mixture
1:7 12.5 100 12.12 ± 0.16 96.96 126 ± 1.62
PEG 6000
SD6 Solid dispersion 1:1 50 100 49.81 ± 0.38 99.62 188 ± 1.43
SD7 Solid dispersion 1:3 25 100 24.77 ± 0.10 99.08 229 ± 1.22
SD8 Solid dispersion 1:5 16.67 100 16.43 ± 0.11 98.56 237 ± 1.60
SD9 Solid dispersion 1:7 12.5 100 12.25 ± 0.04 98.00 253 ± 0.95
SD10 Solid dispersion 1:9 10 100 9.75 ± 0.04 97.50 249 ± 1.14
PM9
Physical 
mixture
1:7 12.5 100 12.37 ± 0.20 98.96 127 ± 2.06
PEG 8000
SD11 Solid dispersion 1:1 50 100 49.83 ± 0.37 99.66 170 ± 1.25
SD12 Solid dispersion 1:3 25 100 24.81 ± 0.19 99.24 195 ± 1.50
SD13 Solid dispersion 1:5 16.67 100 16.46 ± 0.09 98.74 209 ± 1.18
SD14 Solid dispersion 1:7 12.5 100 12.27 ± 0.06 98.16 235 ± 1.56
SD15 Solid dispersion 1:9 10 100 9.77 ± 0.06 97.70 228 ± 1.05
PM14
Physical 
Mixture
1:7 12.5 100 12.37 ± 0.20 98.96 131 ± 2.08
PEG 12000
SD16 Solid dispersion 1:1 50 100 49.82 ± 0.52 99.64 181 ± 1.88
SD17 Solid dispersion 1:3 25 100 24.80 ± 0.20 99.20 202 ± 1.63
SD18 Solid dispersion 1:5 16.67 100 16.45 ± 0.09 98.68 217 ± 1.21
SD19 Solid dispersion 1:7 12.5 100 12.27 ± 0.11 98.16 233 ± 1.70
SD20 Solid dispersion 1:9 10 100 9.77 ± 0.07 97.70 230 ± 1.97
PM19
Physical 
mixture
1:7 12.5 100 12.36 ± 0.17 98.88 141 ± 1.99
PEG 20000
SD21 Solid dispersion 1:1 50 100 49.85 ± 0.51 99.70 152 ± 1.55
SD22 Solid dispersion 1:3 25 100 24.83 ± 0.30 99.33 167 ± 2.01
SD23 Solid dispersion 1:5 16.67 100 16.48 ± 0.14 98.86 186 ± 1.60
SD24 Solid dispersion 1:7 12.5 100 12.29 ± 0.07 98.32 207 ± 1.11
SD25 Solid dispersion 1:9 10 100 9.77 ± 0.06 97.70 228 ± 1.49
PM25
Physical 
mixture
1:9 10 100 9.85 ± 0.12 98.50 149 ± 1.87
Preparation and evaluation of azithromycin binary solid dispersions using various polyethylene glycols 5
operational parameters were as follows: generational 
tension (voltage) of 45 kV; generator current of 40 mA; 
scans step time of 9 sec-1 and scan step size of 0.008° (2θ).
Scanning Electron Microscopy (SEM)
The surface morphology of samples was determined 
using an analytical scanning electron microscope 
(VEGA\\TESCAN-LMU, Czech Republic, equipped with 
thermo-emission cathode [Balzers Union Ltd, Balzers, 
Lichtenstein]). The samples were placed on a sample disc 
carrier carbon stub (10 mm diameter, 3 mm height) and 
coated with gold under vacuum (0.25 Torr). The images 
were generated using a 30 kV electron beam.
Statistical analysis
The data obtained from dissolution and solubility 
studies were statistically compared using the analysis of 
variance [ANOVA] (Hinkelmann, Kempthorne, 2008).
RESULTS AND DISCUSSION 
Drug content and saturation solubility studies
Table I presents the results of drug content and 
saturation solubility test of samples. The calculated 
percentage of drug content for drug-PEG 6000 was 
between the ranges of 97.50% to 99.62%, also the drug 
content of the drug-PEG 4000SDs was in the range of 
97.57% to 99.64%. All determinations were presented 
as mean ± SD of three measurements. The maximum 
solubility of azithromycin in phosphate buffer medium 
(pH = 6.0) was observed as 253 ± 0.95 μg/mL for the 
SD9 (azithromycin:PEG 6000; ratio weight of 1:7). 
Also, saturation solubility of SD4 (drug:PEG 4000) 
with a weight ratio of 1:7 was about 241 ± 1.45 μg/mL 
(Table I). Further studies showed that SD9 had the 
maximum drug solubility. The SD21 (azithromycin:PEG 
20000) demonstrated a minimum drug solubility. 
Consequently, the drug-PEG 6000 or the drug-PEG 4000 
solid dispersions, both with the same ratio of 1:7 (w/w) 
were considered as the best formulations. The probable 
reason for the saturation solubility improvement in 
their formulations was the locally imposed solubilizing 
activity of the carriers used (Bashiri-Shahroodi et al., 
2008; Chaud et al., 2010). Reduced drug particle size, 
decreased particle aggregation and higher wettability of 
drug in the presence of hydrophilic carrier could also be 
considered as the most probable mechanisms for enhanced 
dissolution rate of azithromycin from solid dispersion 
systems. The physical mixtures (PMs) were prepared as 
controls of solid dispersion (SDs) formulations. Based on 
the Table I, SD25 (of PEG 20000) with a further saturation 
solubility compared to other formulations of this group, 
was selected, thus PM25 was prepared. In addition, 
prepared physical mixtures of drug-polymer having higher 
molecular weights, such as PEG 20000 (PM25) due to high 
hydrophilicity and having further -OH functional group, 
demonstrated higher saturation solubility (Adeli, 2014, 
Valizadeh et al., 2004). 
In vitro dissolution studies
Table II and Figure 2 showed the results of in 
vitro azithromycin dissolution. The dissolution of pure 
azithromycin was rather low. Hence, the cumulative 
amount of dissolved drug after 60 min was about 22%. 
The dissolution rate of the azithromycin physical mixture 
was improved, but to a lesser extent than that of the solid 
dispersions. Figure 2B illustrates the comparative drug 
release profile of various solid dispersions and the physical 
mixtures of azithromycin with PEG 6000. The best result 
was observed by PEG 6000 group. The SD9 formulation 
showed the greatest amount of drug release (49.10% at 
60 min) among the investigated solid dispersion samples 
(Figures 2A-2E). The SD21 formulation showed the 
least amount of drug release (30.50% at 60 min) among 
studied SD formulations. The formulations containing 
PEG 4000 (SD4) and PEG 6000 (SD9) dissolved well 
after 30 min and showed higher dissolution efficiencies, in 
comparison with pure azithromycin (DE30 for SD4 = 30.91 
and for SD9 = 31.44, which were the highest DE values 
observed). However, SD9 was selected as the best 
formulation because of the slightly better results obtained. 
Additional tests were performed on this formulation. 
For PEG 20000 polymer, SD24 was selected (35.3% at 
60 min), therefore PM24 was prepared. Perhaps, due 
to establish sink condition and for reasons that will be 
mentioned, SD24 (and consequently PM24) has further 
dissolution compared to other formulations of this group. 
Generally, there seems to be an increase in the solubility 
of azithromycin in the presence of hydrophilic carriers 
surrounding the drug particles. Actually, increasing the 
PEG (4000, 6000, 8000, 12000 and 20000) concentration 
in solid dispersions, up to an optimum amount, resulted in 
an improved drug dissolution. However, further increase 
in polymer content beyond this optimum amount showed 
no additional improvement on drug dissolution. This 
might be attributed to the viscous layer formed around 
the solid particles due to the presence of higher polymer 
concentrations, resulting in a decrease in the diffusion 
coefficient and dissolution of the drug (Giorgetti et al., 
2014; Narasaiah et al., 2011).
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Based on these results, there was significant 
improvement in the dissolution profile of Azithromycin 
in all the prepared solid dispersions (p < 0.05). A similar 
trend was observed with physical mixtures, although in a 
smaller extent. The probable reason for the improvement 
in the dissolution rate in the physical mixtures was the 
local solubilizing effect of PEG 6000 (Patil et al., 2013). 
Overall, the solubility studies showed that the solid 
dispersion method could help to increase the solubility 
of Azithromycin, particularly when used alongside PEG 
6000. Consequently, the dissolution of Azithromycin solid 
dispersion using PEG 6000 (at a drug:polymer ratio of 1:7) 
experienced up to a 100% increase, in comparison to the 
pure drug (2.23 times more). Comparison of the effect of 
increasing the drug solubility, when using different PEGs 
in this study is as follows:
PEG 6000 > PEG 4000 > PEG 8000 > PEG 12000 > 
PEG 20000
The dissolution rate of poorly water soluble drugs 
included within solid dispersions is influenced by various 
factors, including the carrier type, viscosity of carriers 
around drug particles within the dissolution medium 
and the drug: carrier ratio. The chemical nature of the 
drug is also important. Therefore, it is not possible to 
propose a specific process for prediction of the increase 
in the dissolution rate of solid dispersion samples. The 
increase in solubility or dissolution can be explained by 
three reasons: the high hydrophilicity of the polymer, the 
chemical properties of drugs and a reduction in the particle 
size of the drug. 
FIGURE 2 - In vitro dissolution release profiles of pure azithromycin, solid dispersions and the physical mixtures containing: (A) 
PEG 4000, (B) PEG 6000, (C) PEG 8000, (D) PEG 12000, (E) PEG 20000; (n = 3, mean ± SD).
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IR studies
The IR spectra showed that a particular change or 
interaction does not occur between carriers and the drug. 
Figure 3 depicts the IR spectra of pure azithromycin, PEG 
6000 (as the selected polymer), the physical mixture and 
solid dispersions. The spectrum of azithromycin (Figure 
3A) shows characteristic peaks at 1724 cm-1 (C=O stretch), 
1190 cm-1 (C-O-C asymmetrical stretching) and 1049 cm-1 
(C-O-C symmetrical stretching). IR spectrum of the PEG 
6000 also displayed characteristic peaks at 1108 cm-1 
(for C-O-C stretch), 2907 cm-1 (for C-H stretch), and 
3244 cm-1 (O-H stretch) (Figure 3B). On the other hand, 
the peak related to C-O-C stretching bond of the drug in 
1049 cm-1 for samples PM9, SD9 and SD4 shifted to higher 
wave numbers. This can be due to the formation of Van 
der Waals forces between azithromycin and carrier. There 
was no substantial shifting in the position of functional 
groups (Stuart, 2002). According to the IR spectra of 
solid dispersions (such as SD9, Figure 3C) and physical 
mixtures (such as PM9, Figure 3D). Figures 3E and 3F 
illustrates the IR spectra of SD4 and PM4 (as selected 
TABLE II - Dissolution efficiency of pure azithromycin, solid dispersion samples and physical mixtures (n = 3, mean ± SD)
Formulation code Preparation Drug:Polymer (w/w) DE10 (%) DE30 (%)
Azithromycin Pure Drug 1:0 4.50 ± 1.12 14.32 ± 0.95
SD1 Solid Dispersion 1:1 14.22 ± 0.93 23.07 ± 0.94
SD2 Solid Dispersion 1:3 15.45 ± 0.84 23.89 ± 0.76
SD3 Solid Dispersion 1:5 15.80 ± 0.59 27.43 ± 0.76
SD4 Solid Dispersion 1:7 20.76 ± 0.48 30.91 ± 1.38
SD5 Solid Dispersion 1:9 16.16 ± 0.83 29.22 ± 1.04
PM4 Physical Mixture 1:7 14.73 ± 0.92 14.47 ± 1.52
SD6 Solid Dispersion 1:1 14.28 ± 1.37 23.24 ± 0.93
SD7 Solid Dispersion 1:3 15.59 ± 0.39 25.03 ± 0.87
SD8 Solid Dispersion 1:5 15.65 ± 2.19 28.07 ± 0.46
SD9 Solid Dispersion 1:7 18.90 ± 1.48 31.44 ± 0.49
SD10 Solid Dispersion 1:9 17.72 ± 1.38 29.44 ± 1.04
PM9 Physical Mixture 1:7 5.03 ± 2.10 15.18 ± 1.39
SD11 Solid Dispersion 1:1 9.89 ± 1.10 20.63 ± 1.47
SD12 Solid Dispersion 1:3 13.57 ± 0.49 23.35 ± 0.69
SD13 Solid Dispersion 1:5 14.61 ± 0.38 26.78 ± 037
SD14 Solid Dispersion 1:7 19.26 ± 1.69 27.12 ± 0.36
SD15 Solid Dispersion 1:9 15.85 ± 1.46 26.39 ± 2.51
PM14 Physical Mixture 1:7 7.87 ± 1.11 15.80 ± 1.04
SD16 Solid Dispersion 1:1 11.07 ± 1.17 21.64 ± 1.36
SD17 Solid Dispersion 1:3 13.08 ± 0.84 24.17 ± 1.32
SD18 Solid Dispersion 1:5 14.26 ± 1.05 25.09 ± 2.41
SD19 Solid Dispersion 1:7 14.67 ± 1.73 26.87 ± 1.39
SD20 Solid Dispersion 1:9 14.53 ± 0.47 26.12 ± 0.59
PM19 Physical Mixture 1:7 6.48 ± 2.08 16.65 ± 0.34
SD21 Solid Dispersion 1:1 9.70 ± 1.74 20.46 ± 0.68
SD22 Solid Dispersion 1:3 9.88 ± 1.04 22.42 ± 0.37
SD23 Solid Dispersion 1:5 11.10 ± 0.49 23.08 ± 0.22
SD24 Solid Dispersion 1:7 12.84 ± 1.94 24.37 ± 0.50
SD25 Solid Dispersion 1:9 12.68 ± 1.43 25.15 ± 1.23
PM24 Physical Mixture 1:7 8.46 ± 2.01 17.07 ± 1.47
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samples of PEG 4000), respectively. From the figures, 
there was no undesirable chemical interaction between the 
drug and polymer. The main peaks of the drug and polymer 
were clearly distinguished in solid dispersion samples and 
physical mixtures.
DSC studies
DSC as important thermal analyses techniques were 
used to determine the thermodynamic characteristics of SD 
samples. This test was performed for the thermodynamic 
behavior of anhydrous polymorphs of Azithromycin 
and carriers in the present study. The DSC thermogram 
of azithromycin, PEG 6000, SD9 (as the selected solid 
dispersion system) and PM9 (as the physical mixture) 
have been presented in Figure 4. The differential scanning 
calorimetry shows a sharp endothermic fusion peak 
between 109.45 °C to 127.77 °C, which corresponds to the 
melting point of azithromycin (Figure 4A and Table III). 
The sharp endothermic peak of PEG 6000 was exhibited 
at 62.14°C (Figure 4B). A melting endothermic peak 
with decomposition at 144.28 °C can also be depicted. In 
addition, there was no interaction between the drug and 
the polymer according to the observed endothermic peaks. 
The melting peak of pure azithromycin disappeared in 
solid dispersion and physical mixtures, presumably due 
to a transformation in drug structure, from a crystalline to 
an amorphous form (Figure 4).
PXRD studies
Azithromycin crystals display various diffraction 
peaks (Figure 5A) due to their crystalline structure. The 
PXRD pattern revealed sharp peaks at diffraction angles 
(2θ) of 9.56°, 7.72°, 20.67°, 19.59°, 23.80°, 17.31°, 28.68° 
and 26.55°. For PEG 6000, the 2θ value was 19.09° 
(Figure 5B). In the solid dispersion samples studied, there 
were no azithromycin peaks, and this may be attributed 
to structural transformation of the drug molecule from the 
crystalline from into an amorphous form (Figures 5C and 
5E). However, some of the smaller peaks of PXRD of the 
major peaks of pure azithromycin can be detected in SD9, 
PM9 and other samples at the same 2θ value, but with 
much lower intensities, which affirms that azithromycin 
crystal do not completely change into the amorphous 
form in solid dispersion and physical mixtures, and some 
crystalline structure still remains in these samples during 
the preparation process (Figures 5C and 5E). Based on 
these results, the enhancement in azithromycin dissolution 
in the form of solid dispersions can be partly due to the 
structural changes, alongside the influence of the carrier 
itself as well as a reduction in particle size.
SEM studies
Surface morphological studies of the samples 
were carried out using SEM and illustrated in Figure 
6. Cubic-shaped crystals with sharp edges constitute 
the morphology of crystalline Azithromycin powder. 
The morphology of PEG 6000 was needle-shaped. The 
solid dispersion process resulted in the formation of a 
significantly shorter and amorphous length of the PEG 
needles compared to the unaltered azithromycin alone 
(Figure 6). The SEM of solid dispersions reveals the 
existence of irregular particles with several microscopic 
cracks and crevices, which provides additional surface 
for deposition of drug particles. Drug molecules seem 
to be dispersed within the carrier matrix of the solid 
dispersions. Furthermore, a particle size reduction in drug 
molecules is also proposed. These events could help to 
enhance the release profile and dissolution rate of the drug 
molecules. 
FIGURE 3 - IR Spectra of: (A) azithromycin, (B) PEG 6000, (C) 
SD9, (D) PM9, (E) SD4 and (F) PM4.
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TABLE III - Data obtained from the DSC thermograms of 
azithromycin, PEG 6000 solid dispersion, SD9 and physical 
mixture PM9 samples
Sample: Azithromycin PEG 6000 SD9 PM9
TOnset (°C): 22.34 
109.45
21.46 
59.38
57.82 
-
31.17 
57.14
FIGURE 4 - DSC thermograms of: (A) azithromycin, (B) SD9, (C) PM9 and (D) PEG 6000.
FIGURE 5 - PXRD Diffractograms of: (A) azithromycin, (B) 
PEG 6000, (C) SD9, (D) PM9, (E) SD4 and (F) PM4.
Physical stability studies
The selected formulations underwent accelerated 
stability studies, based on ICH guidelines. Study 
parameters were: 40 ± 2 °C and 75 ± 5% relative humidity 
for 120 days (Shel-Lab SMI2 Forced-Air Incubator, USA, 
Sheldon Manufacturing, Inc.). One hundred milligram 
samples were individually stored, kept in glass vials 
sealed with rubber plugs, followed by analysis of the drug 
content and physical changes of the stored samples at time 
intervals: 15, 30, 60, 90 and 120 days. During these time 
periods, the saturation solubility and dissolution rates of 
Azithromycin were re-examined. No significant change 
in the test samples was observed. Hence, the samples 
appeared to remain stable over the study period (Table IV).
Statistical analysis studies
The Pearson correlation test in order to evaluation 
of the relationship between used polymer percentage and 
solubility using SPSS software was carried out. Pearson’s 
E. Adeli10
r with alpha level of 0.05 for PEG 4000, PEG 6000, PEG 
8000, PEG 12000 and PEG 20000 was calculated, the 
results are as follows: 0.7913, 0.8068, 0.8541, 0.8154 
and 0.9309, respectively. In all the groups, solubility of 
the selected samples as SD4, SD9, SD14, SD19 and SD25 
demonstrated significant differences when compared with 
other samples of the same group (p < 0.05). 
CONCLUSIONS 
In this investigation, the solvent evaporation 
approach was used for the preparation of Azithromycin 
solid dispersions. The solubility and the dissolution 
rate of the drug were significantly increased in all of 
the solid dispersion prepared with PEG. The physical 
FIGURE 6 - SEM of: (A) azithromycin [magnification: 500×], (B) azithromycin [magnification: 2500×], (C) azithromycin 
[magnification: 5000×], (D) SD9 [magnification: 2500×] and (E) SD9 [magnification: 2500×].
TABLE IV - Drug content of selected formulations after undergoing stability studies based on the ICH guidelines for storage 
conditions, with was 40 ± 2 °C at 75 ± 5% RH (n = 3, mean ± SD)
Time Pure azithromycin (%) SD4 (%) SD9 (%)
0 days 99.92 ± 1.27 98.08 ± 2.17 98.00 ± 1.57
15 days 99.92 ± 1.02 98.06 ± 1.98 97.95 ± 1.09
30 days 99.91 ± 2.34 97.88 ± 0.95 97.91 ± 1.95
60 days 99.90 ± 0.14 97.75 ± 1.63 97.84 ± 1.03
90 days 99.89 ± 1.22 97.53 ± 2.00 97.44 ± 2.07
120 days 99.88 ± 0.78 97.29 ± 2.67 97.37 ± 1.97
Preparation and evaluation of azithromycin binary solid dispersions using various polyethylene glycols 11
mixture samples had lower dissolution rates than the solid 
dispersion systems. The best result was obtained from 
solid dispersions containing azithromycin:PEG 6000 in 
a ratio of 1:7. The amount of azithromycin released from 
this solid dispersion sample (SD9) was more than 49% in 
60 min. Greater wettability of the drug by this hydrophilic 
carrier, as well as an increase in surface area (Adeli, 
2014) seems to be the main reasons for the increase in 
drug dissolution rate. Hence, the solid dispersion method, 
using a hydrophilic carrier such as PEG 6000, could be 
considered as an appropriate technique for dissolution 
enhancement of azithromycin, which is a poorly-soluble 
drug.
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